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Background: The Electronic Prescription Service release Two (EPS2) is a new national healthcare information and
communication technology in England that aims to deliver effective prescription writing, dispensing and
reimbursement service to benefit patients. The aim of the study was to explore initial user experiences of
Community Pharmacists (CPs) using EPS2.
Methods: We conducted nonparticipant observations and interviews in eight EPS2 early adopter community
pharmacies classified as ‘first-of-type’ in midlands and northern regions in England. We interviewed eight
pharmacists and two dispensers in addition to 56 hours recorded nonparticipant observations as field notes.
Line-by-line coding and thematic analysis was conducted on the interview transcripts and field notes.
Results: CPs faced two types of challenge. The first was to do with missing electronic prescriptions. This was
sometimes very disrupting to work practice, but pharmacists considered it a temporary issue resolvable with minor
modifications to the system and user familiarity. The second was to do with long term design-specific issues.
Pharmacists could only overcome these by using the system in ways not intended by the developers. Some felt that
these issues would not exist had ‘real’ users been involved in the initial development. The issues were: 1) printing out
electronic prescriptions (tokens) to dispense from for safe dispensing practices and to free up monitors for other uses,
2) logging all dispensing activities with one user’s Smartcard for convenience and use all human resources in the
pharmacy, and, 3) problematic interface causing issues with endorsing prescriptions and claiming reimbursements.
Conclusions: We question if these unintended uses and barriers would have occurred had a more rigorous
user-centric principles been applied at the earlier stages of design and implementation of EPS. We conclude that,
since modification can occur at the evaluation stage, there is still scope for some of these barriers to be corrected
to address the needs, and enhance the experiences, of CPs using the service, and make recommendations on how
current challenges could be resolved.
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The electronic prescription service (Release 2)
In England, it is part of the government’s agenda to enable
the writing and dispensing of electronic prescriptions to
patients. The Electronic Prescription Service (EPS), re-
leased in stages one (EPS1) and two (EPS2) was designed
to meet this agenda. Our study focused on EPS2. Sudgen
and Wilson [1] who piloted and evaluated early models of
the EPS, also known as the Electronic Transmission of
Prescriptions, documented the concept behind its devel-
opment. Rai [2] explains the process of writing and dis-
pensing EPS2 prescriptions in detail, and Gourdrey-Smith
[3] explains its functions. In summary, EPS2 is informa-
tion and communication technology that automates
prescription links between prescribing, dispensing and
pricing bodies for better patient care in the following
simplified format:
 Patient to General Practitioner (GP): GP (or
designated prescriber) writes prescriptions
electronically.
 Electronic prescription to Spine: The electronic
prescription is sent to and stored on a national
database called the N3, commonly known as the Spine.
 Spine to community pharmacies: Community
Pharmacists (CPs) and their teams
 (CP professionals) in pharmacies nominated by the
patient to dispense their prescriptions can access
and download the prescription from the Spine, and
dispense it to the patient.
 Community pharmacies to remuneration agency:
The remuneration agency, formerly known as
Prescription Pricing Authority (PPA), is now called
NHS Prescription Services. NHS Prescription
Services receives prescriptions from dispensers, such
as community pharmacies, calculates relevant
payments for the items dispensed and remunerates
dispensers for these. With EPS2, details of items
dispensed are sent directly to NHS Prescription
Services electronically.
Therefore, prescribers, dispensers, patients and the
pricing authority are key stakeholders in the successful
implementation of the EPS2. Figure 1 shows the original
EPS2 architecture given to the study team by the initial
overseeing body called Connecting for Health (CfH).
While the wider scope of the research project was to
evaluate changes in various forms made by EPS2 to all
stakeholders, in this paper we focus on community phar-
macies. CP professionals were proposed to be one of the
key beneficiaries of the EPS2 for being able to provide a
better quality service because of improved work practices.
The pharmacist from the first adopter pharmacy began
dispensing EPS2 prescriptions in July 2009. AlthoughEPS2 was still undergoing development at the time of data
collection (February–September 2011), early adopters
were dispensing between 10% and 40% EPS2 prescriptions
(Table 1).
Since 2011, the National Health Service (NHS) in England,
including EPS2 has been undergoing re-organisation.
EPS2 was originally part of the National Programme for
IT (NPfIT) to make Primary and Secondary care electron-
ically interoperable in England [4], but it was designed to
operate independent of other NPfIT programmes [2-5].
When NPfIT was dismantled in 2011, some of its stand-
alone programmes such as EPS2 were retained. On 31
March 2013, the overseeing body of the NPfIT pro-
grammes CfH ceased to exist. Many of its functions,
including the Electronic Prescription Service, have
transferred to the new Health and Social Care Informa-
tion Centre (HSCIC). On 1st April 2013, responsibility
for supporting pharmacists in using these services
transferred to NHS England (formally known as the
NHS Commissioning Board) [6]. The EPS2 national
implementation programme is still on going.
The aim of the study was to explore initial user experi-
ences of CP professionals, and to ask if their needs were
met concerning the development and implementation of
EPS2. In the following, we briefly discuss key factors in
new technology adoption and frame our research ques-
tions within these contexts. We then discuss our meth-
odology, present and discuss our findings. Please note
that we use ‘early adopters’ to denote sites involved in
the early stages of EPS2 implementation. Also, note that
we use the term ‘real user’ to denote actual users of the
system. In this paper, ‘real users’ are practising commu-
nity pharmacists and their teams, and not any other type
of pharmacist.
Some key factors in successful system delivery
or adoption
New systems or innovations are usually developed to
solve a problem or aid a process. A system development
usually comprises several iterative stages in its lifecycle
such as specification or problem-definition, feasibility
study, analysis, design, implementation, evaluation and
maintenance. When a new system is being developed,
many factors influence the planning stage [7]. Key factors
include: a) Financial aspects, which comprise of the cost of
the system and the overall benefits. b) Technical aspects,
what can be accomplished by using existing technologies?
and c) Social factors, which comprise changes the new sys-
tem will be making to current work practices of the users,
and how users will engage with the system comprehen-
sively. Some authors recognise this last factor, the social
factor, as the most important in a system development
concerning the systems acceptance and diffusion [8,9].
Rogers, for example, names five determinants including
Figure 1 Original EPS2 model and architecture (given to study team by Connecting for Health).
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ing values and practices as key factors in successful
adoption, and argue that the innovation is usually what
changes to suit the user and not the other way round
[9]. Many systems fail or fall into disuse not because of
technical failure, but in how the technology is matched
to the social environment [10]. The disengagement by
users, or a poor user experience directly affects financial
and technical factors and can render the system unusable
and detrimental [11-15]. Consequently, there needs to
be a continuous engagement between the system and
the social environment to render a product usable [15].
In theorising the role technology plays in social struc-
tures, Greenhalgh and Stone [16] explained that, theTable 1 Descriptive information of data collection sites
Site Percentage of EPS2 dispensed at time
of interview
EPS2 live
since
1 20% 07.2009
2 35% 12.2009
3 18% 09.2010
4 Information not supplied but noted to be greater
than 10%
06.2011
5 40% 08.2010
6 10% 08.2010
7 10% 07.2010
8 16% 05.2010technological component of social structures may be
supported when people choose to use the technology,
and, not supported when they actively refuse to use it
or, importantly, cannot use it at all or in the ways they
would like.
In healthcare, Benn et al. [17] lists “size, regional loca-
tion, internal structure, management processes, history,
external regulatory environment, culture and leadership”
as key variables that contribute to successful delivery of
care systems. However, similar to other theories, em-
phasis is placed on social elements as a key factor in
technology adoption. Harvey et al. [18] for example con-
ceptualised that “socio-technical interdependence” is a
key dimension in the adoption of new technology into
pharmacy work practice. Therefore, before new technol-
ogy is effectively integrated into work practice, it is im-
portant to note how the intended users interact with
existing technologies in that environment. In their study,
which focused on the approaches to, and experiences of
user engagement of the adoption of Lorenzo software
into national EHR system in England, Cresswell et al.
[19] placed emphasis on user (dis)engagement. For ex-
ample, because real users such as hospital staff were not
included in the system development process, this alienated
them during the implementation process as they felt the
system was then not sufficiently customised for their
needs. Furthermore, Gagnon et al. [20] found that the
boundary between barriers and facilitators in electronic
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mended studies to be conducted from a variety of user
group perspectives. Within these contexts, we frame our
research questions: what were CP professionals’ experi-
ences of EPS2, what were their perceptions and attitudes
toward the new system, and what can be learned to im-
prove user experience and feedback to the implementers
in terms of meeting their needs?
Methods
Data collection
The research was part of the national CfH evaluation
programme commissioned by Department of Health to
evaluate how EPS2 will alter work practices. The research
protocol was designed by a multidisciplinary study team
consisting of social scientists, academic and practising
pharmacists and a general practitioner. The methodo-
logical framework was developed from literature reviews
on ‘user perception’ studies of new technologies [21-23],
electronic prescription adoption in healthcare [24-29] and
listed potential benefits of EPS2 according to CfH [30].
Rather than using standardised variables in ‘user per-
ception’ study models such as perceived ease of use
and perceived usefulness, we adopted a constructivist
(qualitative) approach by using flexible themes based
on user-perception studies, such as user’s perceptions
on positive and negative issues, perceived benefits, and
opinions on removing the system. This approach allowed
us to delve deeper beyond standardised variables into
users’ candid perceptions.
The data were collected between February and September
2011. In terms of sampling, we obtained a list of pharma-
cies classified as early adopters from CfH and selected
pharmacies that were ‘live’ and dispensing above 5% elec-
tronic prescriptions. The eight pharmacies that fell into
this category were in the midland and northern regions of
England (Table 1). Sites with different computerised phar-
macy management systems were chosen to get divergent
perspectives. Other variations in the sites sampled in-
cluded type of ownership of the pharmacy (independent
or chain), geographic location and different software
suppliers. Due to the small number of test sites (initial
adopters) at the time of the study, providing detailed in-
formation in this paper would breech confidentiality
and commercial sensitivity agreements. Permissions were
sought from approval bodies at each of the study sites, in-
cluding Primary Care Trusts, research governance teams,
benefit realisation teams and informatics leads. The study
protocol was submitted to the Cambridgeshire Research
Ethics Committee who classed the study as a service
evaluation.
Data were collected using ethnographically informed
mixed methods including observations, formal (recorded)
and informal interviews, and shadowing of pharmacyprofessionals. Our chief participants were pharma-
cists/pharmacist proprietors as they had overall insight
of the EPS2 integration into work practice. We conducted
audio-recorded interviews with all chief participants. We
also audio-recorded one accredited checking technician
and one dispenser as additional participants. We con-
ducted 10 audio-recorded in-depth interviews. The inter-
views took 30 minutes to one hour, with transcripts for
each averaging 3700 words. Notes were recorded from the
participants too occupied with work to give audio-
recorded interviews. While the pharmacists were generous
in allowing us access to their sites and permitting inter-
views, the busy nature of the job meant there were time
constraints.
Analysis
Overall, 37, 200 words from the transcripts were ana-
lysed besides the field notes. Both types of qualitative
data were analysed using line-by-line coding (Figure 2)
and thematic analysis. Each line was coded into sub-
themes and into themes. Themes were then recoded
into positive and negative issues. This identified experi-
ences associated with usability and user experiences
thereby achieving a bottom-up analysis. EPS is a stan-
dardised system that has to be integrated with different
pharmacy dispensing systems, meaning CPs have a
choice of who their ‘pharmacy system-EPS’ supplier is
[31]. The eight sites had different pharmacy system sup-
pliers. Bearing this in mind, we focused our analysis on
common issues among the sites to remove supplier spe-
cific issues.
Analysis showed that CP professionals were overall posi-
tive about the system and wished for it to be retained and
improved, instead of being discontinued [32]. They were
however facing two types of challenges with the system.
The first type of challenge was caused by missing elec-
tronic prescriptions. Sometimes, when the prescriber
wrote the prescription, pharmacists nominated by the
patient to dispense the prescription could not see or
download the prescription for dispensing. This issue
was especially challenging for pharmacists as there were
different causes with no adaptable solution within phar-
macy work practice. Pharmacists, however, considered
this a teething issue that could be resolved by small
modifications to the system [32]. The second type of
challenge was considered long-term and was specific to
the system design. Although these design specific issues
were adaptable into work practice with ‘add-on’ designs,
pharmacists thought these issues were present because
they were not involved in the system design and devel-
opment. We decided to present the two challenges in
two papers to allow us to discuss the issues (with user
commentaries) in detail. In this paper, we present our
set of second type challenge in the EPS2 adoption.
Figure 2 Sample line-by-line coding method.
Figure 3 NHS EPS2 patient and carers information leaflet
in England.
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We found there were some essential user needs that
were not met. These caused users to interact with the
system in ways not intended by the system developers,
and interfered with how CP professionals experienced
the system. These were, 1) dispensing from printed-out
tokens instead of screens, 2) using one Smartcard to log
all dispensing activities by different staff, and, 3) prob-
lematic interface for claiming reimbursements.
Printing tokens
A key aspect of the EPS2 design was to decrease paper
prescriptions by electronically writing and dispensing
prescriptions. Figure 3 shows how the system was de-
scribed in the patient and carer information leaflet [33].
This means prescribers have to record the medications
electronically on their computer screens and dispensers,
after downloading the prescription, can dispense them
directly from the screen without any need of a paper.
The pharmacists we interviewed would not dispense
from a computer screen, as they feared it would com-
promise safety. They felt that the best practice was to
have a paper prescription beside the medicines they were
dispensing. This enabled dispensers to check medica-
tions they were picking from the shelves against the
paper in hand, and allowed pharmacists to conduct the
final professional check of the dispensed items from any
location in the pharmacy. Pharmacists felt that dispens-
ing from computer screens would not only hinder thisform of verification but restrict access to the computers
as the following excerpts demonstrate:
I don’t know whether their initial aim was to dispense
off the screen or check off the screen, you know, but I
wouldn’t check off the screen or dispense off the screen
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defeats the purpose of the electronic prescriptions”
(Site 3, Pharmacist).“Often, you are too busy in a pharmacy to be able to
dispense from the screen. You might have to run your
labels off and you need something to check from”
(Site 1, Pharmacist).“I don’t ever see—I don’t know if you could ever get rid
of the paper aspect, because I think that I wouldn’t
like to check three prescriptions of five items, fifteen
items looking at a TV screen. I think I would end up
kind of cross-eyed. It’s much easier to look at a piece of
paper” (Site 8, Pharmacist).
CPs felt they would have made this known had they
been consulted in the EPS2 design. Consequently, in-
stead of directly dispensing medication from computer
screens, community pharmacists have deviated from the
original EPS2 design by opting to print out the elec-
tronic prescriptions after downloading them onto their
screens. These printed electronic prescriptions, com-
monly known as tokens, were then used to dispense
medications. Although tokens are not legal prescriptions,
they provide a hard copy of data from the electronic pre-
scription, so were accepted by pharmacists for use in
dispensing. In addition, printing the tokens enabled pa-
tients to have a physical possession of their medication
information, as explained by this pharmacist:
“You might need the token to be able to check your
items to the labels. Also, you need the repeat slip for
patients attached to the token. Patients aren’t going to
be able to order again unless they get something in their
bag and they can order next time. To do that you need
to print the token. If the patient is exempt in some way
or pays for the prescription, it has to be filled in on the
back if they are not age exempt. If they are under 16, or,
over 60, you don’t have to use that paper copy. However
you still need the repeat slips, you still need to fill in the
exemption and get it signed on the back to show that the
patient has an exemption or has a certificate to show
that they don’t pay” (Site 1, Pharmacist).
On 10 October 2012, E-health Insider (EHI) featured an
article that showed plans for the NHS to be paperless by
2015 [34]. From these interviewee commentaries, it is ap-
parent that the paper-free design of EPS2 is challenging to
its users in practice. Paper prescriptions are small, light
and mobile and can be annotated, for example, in the final
safety check the pharmacist can tick each item on the
paper as it has been confirmed correct, allowing them to
be interrupted and regain their place without losingaccuracy. Perhaps other ‘paper-free’ alternatives could be
explored such as using tablets to take screenshots of the
electronic prescription for portable dispensing. A chal-
lenge in relation to printing of tokens is the additional
cost; that pharmacists take this on without reimbursement
shows the printing has value to them.
Smartcard policies
EPS2 was designed to be a Smartcard system to enable
access to the Spine. Health professionals who need ac-
cess to the Spine have to apply for Smartcards from the
Registration Authority usually the local Primary Care
Trust (PCT) [3]. Since EPS was designed to use ‘a single
card’ model of access, individual Smartcards are required
for each user. Users cannot share Smartcards or even
share access sessions. The purpose of this is to have an
audit trail of users of the Spine [3,35]. Generally, the
Smartcard system was not used as intended. Community
pharmacies are places of constant rapid physical acts ful-
filling the prescription; time at a terminal is a relatively
small part of this and terminals are often used by several
people. CPs felt that this was the more practical usable
method since multiple users did not have to keep log-
ging in and out of the system. Consequently, the first
person who logged into the system left their Smartcard
in until they finished work for the day then someone else
would take over as the main logged-in user as the fol-
lowing excerpt demonstrates:
“We do all have individual Smartcards. We all can
use an individual Smartcard. It would just tend to be
whoever has been logged in first thing in the morning
as the person who would end up doing that most of
the day. S goes home at half past four, for instance,
and then someone else would have to do it. SE would
probably log-in, she leaves at six and then whoever is
in this evening would log-in. It just depends really as
to who is in first thing in the morning. But yeah, that’s
just the way it goes” (Site 5, Pharmacist).
The main reason behind this approach was conveni-
ence as the logging in and out by different users would
significantly interfere with workflow and reduce prod-
uctivity, especially at peak hours. Some pharmacists
also argued that the reason behind using one Smartcard
was to distribute the workload as widely as possible. In
the following, pharmacists give more explanation of
their reasons for not using Smartcards for each mem-
ber of staff:
“No, we should do [log-in individually], but we don’t.
Because three dispensers, well three people, have the
Smartcard in the pharmacy and in fact there is
probably five people in the pharmacy that can do all
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Smartcard [rule], two people would be isolated away
from the computer not being able to dispense. I log-in
at the beginning of the day and it’s left there. My re-
sponsibility if anything happens untoward, but I can’t
understand what it could be, because they are doing
NHS prescriptions all the time anyway, and they are
used to doing that, and they’ve signed the Data Confi-
dentiality and Data Protection Act” (Site 8,
Pharmacist).“We keep our own. We’ve [each] got a screen, a
monitor each, maybe because there is only two of us so
X keeps her Smartcard and if I’m not in and if there is
a locum in, X will download all the prescriptions,
because well, our regular locum does have her own
Smartcard and she will bring that and use that. But if
you use an agency locums, they wouldn’t necessarily
have a card and then everything would go through X”
(Site 6, Pharmacist).
Clearly, this was not how the system was designed,
continued use this way could breach security and might
become an issue if pharmacists have access to patients’
electronic health records. Since EPS2 is still undergoing
product development through modifications, perhaps
this feature could be modified in a way that would not
require the logging of every user’s activity.
Prescription endorsing interface
Getting the interface right in any system development is
often the biggest challenge. The interface of a system is
a self-contained feature and includes getting a range of
multiple items right such as the aesthetics, clarity in dir-
ection of use, colours, and user’s emotional connection
with it [36]. A key interface issue that has arisen at the
evaluation stage of the EPS2 is interacting effectively
with the endorsing and claiming interface. When pre-
scriptions are dispensed, pharmacists have to send off
the prescription details to NHS prescription service,
which has several functions including reimbursing the
price of the purchased medicines and the professional
fees incurred by pharmacists. Under the paper system,
the prescriptions are collated and sent off manually to
the pricing body; under the EPS2, this is done electron-
ically using the ‘endorsing and claiming’ interface. The
problem some pharmacists appeared to be having with
EPS2 interface is effectively interacting with it to claim
back charges incurred after dispensing. Since a Com-
mon User Interface (CUI) that would integrate with
different types of pharmacy systems was not developed
[37], some pharmacy systems adapted better to endors-
ing and claiming than others. Consequently, some
pharmacists had more issues than others. However, acommon concern involved ‘NCSO’ claiming, as this
pharmacist explains in detail:
“NCSO means No Cheaper Stock Obtainable.
Normally everything gets endorsed by the computer, by
the endorsing machine. Certain items have to be
endorsed manually [not automatic but completed on
screen] if it’s specialised and controlled drugs or
NCSO. Every month, the Department of Health, they
produce a list. Sometimes it’s quite a big list, ten,
fifteen items and sometimes it’s only one or two items.
For example, this month, 20 mg tablets is on the
NCSO list. That list only gets published about the
tenth of each month. Everything I’ve done from the
first to the tenth, I don’t know whether that item is
going to be on the NCSO list. With NCSO, what I have
to do, I have to sign it, and I have to date it and I
have to put the price I’ve paid for it. So the (Inaudible
00.12.22) might be £2.50 for example. What I’ve paid
for it is £10. If I can’t endorse it as £10 I lose £7.50.”
(Site 3, Pharmacist).
The encouragement by NHS Connecting for Health of
pharmacists to regularly claim electronically for reim-
bursement (to reduce high flows at the end of the
month) means that they may not get reimbursed for
NCSO list items that they have dispensed and sent off
for reimbursement early in the month. This issue has led
pharmacists to become concerned about losing income
as noted in the following extracts:
“We are still having problems transmitting a lot of data
to pricing bureau. Last month, I think we had about two
dozen in total that wouldn’t allow them to be
electronically submitted. Our main problem is, when
you come to do your ETPII endorsing on [software
system 2], I think it was the same on [software system 1].
If you supply, say aspirin tablets and you say aspirin
tablets and it has a manufacturer next to it Tabba
Actevis. What we’ve done is, we’ve obviously ticked the
NCSO button. Because we’ve logged in, we assume that’s
as good as a signature for them, which it is, apparently
and we sent the data off for months and months and
months. We haven’t been paid for any NCSO for
months” (Site 2, Pharmacist Proprietor).“When we endorse, often there is prescriptions that just
won’t go. They won’t send so we’ve [wrongly] paid for
numerous prescriptions where I’m going to have to sit
down with X from the PCT [Primary Care Trust] next
week and go through them all and see whether we can
chase these payments. Some of them are over six
months old, so then we’d have to request the doctors to
reissue. One of the endorsing issues was for PIs imports
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pack. The C programme was asking for a
supplementary payment, which is not required for
this item. But because I’ve spoken to pharmacists who
work in a pharmacy and obviously [they’ve] spoken to
a pharmacist who has been stuck in their computer
room for the last ten years, they don’t realise what’s
going on. They basically said to us, well, for it to go
you need to put a payment in or a supplementary
payment. They said, well, just put a penny in and
they will pay you for the right amount. Some of these
cost a lot of money. I said well, I tell you what then, if
they are going to pay the right amount, why should I
put a penny in and risk it. I’ll put £10,000 in shall I,
and then I will get paid still the right amount and
not the £10,000. If it goes wrong, I’m at least on the
right side of it. So then I get the PPA ringing me up
and wondering why I’ve endorsed a load of
prescriptions for millions of pounds and then again
I’m under stress again, because the PPA are accusing
me then of trying to claim lots of money, I was just
trying to prove a point” (Site 1, Pharmacist
Proprietor).
These detailed commentaries define an interface prob-
lem that appears to be causing monetary stress to some
pharmacists. Since the interface was not user-friendly,
users had to look for alternative ways to claim reim-
bursements of NCSO items.
Discussion
Usability and user experience: meeting user needs
In our findings, CP professionals’ needs were not met,
particularly in how the system was designed so they
had to find ways to adapt them to their needs. The us-
ability and user experience issues identified did not
conform with key facilitators of technology adoption
such as ease of use and compatibility [9,38]. While an
explanation of the unintended uses could be attributed
to CPs collective resistance to change, it does not ap-
pear as if the system was tailored to their needs in the
first place, which is a key facilitator of technology adop-
tion. A different explanation to these design specific is-
sues could be due to the lack of CPs’ perspectives in the
design and development of the EPS2, as demonstrated
by this comment: “But because I’ve spoken to pharmacists
who work in a pharmacy and obviously [they’ve] spoken to
a pharmacist who has been stuck in their computer room
for the last ten years, they don’t realise what’s going on”.
Whether or not this statement is justified, in the following,
we use the concept of user-centric principles to explore
and discuss how the involvement of CPs as a key user
group in the EPS2 development might have enhanced
their experience.User-centric approaches and active user involvement
To meet user needs in terms of system design, users are
often involved in the system development process [38].
Applying user-centric principles, such as user-centred
design, which moulds the design of the system to suit its
intended users, is recognised as best practice [39]. Stud-
ies have shown that national healthcare Information and
Communication Technologies (ICTs) development such
as Electronic Health Records (EHRs) tend to fail in user
engagement [19]. A key reason for this is, users tend to
be excluded from the initial stages, and are usually in-
volved only at later stages, thereby making critical modi-
fications to the system design either expensive or
impossible [40-42].
Involving users in a new system development can take
several approaches. While active involvement of users is
sometimes seen as overindulging by allowing users to
specify unnecessary functions [43], the application of
user-centric design is usually seen and adopted as best
practice in a system development. User-centred design,
sometimes also referred to as ‘user-centred system de-
sign’ is a human-computer interaction strategy to in-
volve end-users in a new system or service development.
The meaning of UCD has become vague since it was
coined by Norman and Draper [44], however, its aim is
to place emphasis on user engagement, and improving
how the user experiences the system when implemented.
It focuses on users by learning about the context of their
work, the environments they work in, and their needs
for usable products [45]. In short, the aim of UCD is to
create a better user experience for the people for whom
the system was designed. In practice, UCD faces many
challenges as it can be applied using several approaches
[39,45]. Using common approaches to UCD, Gulliksen
et al. [39] developed key principles that underpin its ap-
plication in a system development, and these are:
 The early focus on users’ work practices and tasks to
control the development,
 Active user participation in the analysis, design,
development and evaluation,
 Early prototyping to gradually build a shared
understanding of user needs as well as future work
practices,
 Continuous iteration of designed solutions,
 Multidisciplinary design teams, and
 Integrated design that involves the system, the work
practices, online-help, training, organisation, etc.
The theory about the application of these principles is
that they will improve the usability of the product and its
User Interface (UI) such as ease of use, efficiency, reduced
error, and user satisfaction. UI has especially become a
current focus of UCD practices as it enables users to
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[46]. When detailed iteration takes place in the later
stages of the development, it is more expensive if the
design follows a stage-gate model from conceptual to
detailed design. Meaning each design step sets con-
straints on the next and hence any change in design at a
later stage is more expensive than at an earlier stage
[47]. Using this perspective, we put into context how a
UCD approach could have been used to mould CP pro-
fessionals’ experience of EPS2.
Putting user-centeredness into context
While reasons such as lack of technical and other forms
of support, no added value in terms of finance, or even re-
sistance to change could be explanations for why CPs
could not interact effectively with the design of EPS2
[9,20,38], active user-involvement could be another ex-
planation. Firstly, in terms of dispensing directly from
screens, CPs elected to print and dispense from tokens be-
cause various usability requirements such as equipment
sharing, job sharing, multi-tasking, and providing advisory
slips to patients made dispensing directly from screens
challenging. This issue was evident during the piloting of
various models at the concept evaluation stage [1]. How-
ever, it appears the issue was not explored further or re-
solved before latter stages, as it would have also been
evident during the prototype testing stage. Secondly, in
terms of CPs electing to use a single smartcard for mul-
tiple users, a key practice of UCD is to perform detailed
task analysis of users’ work to design systems that would
improve (not interfere) with workflow [45]. Using multiple
user log-ins to achieve accurate audit trails appears a
feasible concept. In practice however, the concept was
challenging for CP professionals as it interfered with
workflow. They therefore adapted the Smartcard’s us-
ability to suit their needs by using one Smartcard to
serve multiple users. This issue was evident in our EPS2
pre-implementation study of pharmacy work practice as
pharmacists showed signs of not using EPS2 Smartcards
as intended. We fed back our findings to participating
PCTs as part of our formative evaluation [48]. However,
this issue could have been evident much earlier at the
concept evaluation stage when the idea of EPS2 (and
this function) was being marketed to users. It could also
have been identified during the user’s task analysis or
even the prototyping stages of user-centric approaches.
Lastly, since a common user interface to integrate with
different types of pharmacy managing systems was not
developed, pharmacists had to find ways to deal with
the NCSO claiming and endorsing function. Prototype
testing by users from various dispensing systems could
have aided a better NCSO UI design across all systems.
We do not know to what extent user-centric approaches
were used and how rigorously they were applied as wecould find very little information on this. It is possible that
these design issues were identified at earlier stages but
were not resolved at later stages of the system develop-
ment, however, the purpose of active user involvement is
to mould the system to user needs before it becomes too
expensive to resolve [47]. While, there may be other ex-
planations for why users could not integrate these EPS2
features into work practice, our study suggests that lack of
active CP user groups in the early stages of system devel-
opment may have been the main problem. While engaging
users at later stages allows them to touch and feel the ac-
tual product and not just a concept, active involvement in
the initial stages is more participatory and allows users to
contribute to the design based on their needs. The EPS2
at its evaluation stage clearly showed some important
technical barriers that could have perhaps been eliminated
had real users been meticulously and actively involved in
the initial stages of its development.
Strengths
We have built on work done by Cresswell et al. [19] on
user engagement by focusing on community pharmacists
and their teams as a key user as key user group in the de-
livery of the national Electronic Prescription Service (EPS)
in England. Our focus on English community pharmacies
(and primary care) in this paper contributes new know-
ledge because most of the user-perception literature on
national electronic prescriptions systems relates to other
parts of Europe and America, and focuses on general
practice (GP) or secondary care [20,24-29].
Limitations
We emphasize that these are only preliminary findings
from early adopter sites, and suggest further studies to
establish how the system operates when more mature.
We acknowledge that with a small sample our findings
may not be generalisable to other community pharma-
cies, or fit with the experiences of pharmacies that
adopted EPS later. However, our aim is to draw attention
to involving user group perspectives into systems’ devel-
opment regardless of whether the issues were still per-
sistent at the time of writing this article. Overall, there is
scope for further studies once EPS2 has been imple-
mented more widely. This could help determine whether
issues we have identified have been resolved and/or
whether new issues have emerged.
Conclusions
Using detailed commentaries from the study of early
adopters, we have drawn attention to some key issues in
national healthcare system development from a commu-
nity pharmacy perspective. Firstly, pharmacy professionals
needs were not meet in terms of the system design as they
had to appropriate certain aspects of the system to suit
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be made publicly available to reassure users and to make
the development process transparent. Thirdly, our findings
suggest that involving real users in the service or system
design from the initial stages and throughout the develop-
ment life cycle could help enhance usability and user expe-
riences, or at least flag up cases in which national policy
will be detrimental to local activities. While we acknow-
ledge that many pharmacists were over all in favour of the
system, EPS2 at this early evaluation stage clearly showed
some key usability and user experience barriers that could
have perhaps been eliminated had real users been meticu-
lously and actively involved in the initial stages of its devel-
opment. We conclude that since EPS2 at the writing of
this article is in its evaluation stage, these issues can still be
addressed through modifications and perhaps system re-
design, and would help meet the needs of community
pharmacies and improve their user experience.
Recommendations
Our recommendations take into account that the EPS is
still evolving, and therefore need long term (or futuris-
tic) solutions to the design challenges faced by pharma-
cists, if a paperless NHS is to be achieved.
1. Paperless alternatives to the prescription should be
developed and assessed with users.
2. Alternative governance arrangements, or different
technology (such as biometric identification), is
needed to allow several different users to use the
same terminals without delay.
3. In terms of interface challenges of claiming and
reimbursement, pharmacists could be encouraged to
make NCSO claims, after the list is published by the
Department of Health, while EPS is evolving. In the
long term, we recommend that pharmacists make
their collective voice heard regarding this issue so
that a more acceptable ‘standardised’ interface could
be achieved.
4. Pharmacists should form powerful user groups to
work with each of the pharmacy management
system suppliers.
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